Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to...
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting [beta]2agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
About this item
Full title
Author / Creator
Publisher
London: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
London: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. Adults with uncontrolled persistent asthma who are receiving medium-to-high-dose inhaled corticosteroids plus a long-acting β2agonist require additional treatment options as a...
Alternative Titles
Full title
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting [beta]2agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1802783675
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1802783675
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(16)30307-5
